| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
NeoComplete Paraneoplastic Evaluation with Recombx®
Test Code91636
CPT Codes
86255 (x3), 86341, 83519 (x2), 86596, 83520 (x8)
Includes
Recombx® Amphiphysin Autoantibody Test
CASPR2 Antibody Test
GAD65 Neurological Syndrome Antibody Test
Ganglionic AChR Antibody Test
LEMS (VGCC) Antibody Test
LGI1 Autoantibody Test
NMDA Receptor (NR1-subunit) Autoantibody Test
Recombx® CAR (Anti-Recoverin) Autoantibody Test
Recombx® CV2 Antibody Test
Recombx® MaTa Autoantibody Test
Recombx® Ri Autoantibody Test
Recombx® Yo Autoantibody Test
Recombx® Zic4 Antibody Test
Recombx® Hu Autoantibody Test
VGKC Antibody Test
CASPR2 Antibody Test
GAD65 Neurological Syndrome Antibody Test
Ganglionic AChR Antibody Test
LEMS (VGCC) Antibody Test
LGI1 Autoantibody Test
NMDA Receptor (NR1-subunit) Autoantibody Test
Recombx® CAR (Anti-Recoverin) Autoantibody Test
Recombx® CV2 Antibody Test
Recombx® MaTa Autoantibody Test
Recombx® Ri Autoantibody Test
Recombx® Yo Autoantibody Test
Recombx® Zic4 Antibody Test
Recombx® Hu Autoantibody Test
VGKC Antibody Test
Preferred Specimen
2 mL serum
Minimum Volume
0.5 mL
Instructions
Serum must be separated from whole blood within 48 hours of collection.
Note: Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Note: Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 72 hours
Refrigerated: 21 days
Frozen: 28 days
Refrigerated: 21 days
Frozen: 28 days
Methodology
Automated Nanoliter Scale Immunoassay • Enzyme Linked Immunosorbent Immunoassay (ELISA) • Radioimmunoassay (RIA) • Immunofluorescence Assay (IFA)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Sets up 2 days a week.
Clinical Significance
Anti-Hu, anti-CV2, anti-Yo, anti-Ri, anti-CAR, anti-Ma, anti-Ta, anti-Zic4 antibodies, anti-voltage gated calcium channels (VGCC), anti-P/Q type and voltage gated potassium channels (VGKC), anti- Ganglionic AChR, anti-Amphiphysin, anti-NMDA receptor (NR1-subunit), anti-LGI1, anti-CASPR2, and anti-GAD65 are found in patients with the acute or subacute onset of limbic encephalitis, brainstem encephalitis, focal cortical encephalitis, myelitis, cerebellar degeneration, opsoclonus/myoclonus, retinopathy, sensory neuropathy, autonomic dysfunction, Stiff Person Syndrome and/or Lambert-Eaton Myasthenic Syndrome. This semi-quantitative assay may be useful in monitoring therapeutic responses in select cases.
